Israel’s Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays
NEW YORK – Israeli liquid biopsy startup Nucleix is taking aim at the US cancer detection market with diagnostic assays for early-stage cancers such as lung and esophageal that frequently occur in smokers. Specifically, the Rehovot-based firm hopes to launch a research-use-only lung cancer diagnostic assay next year, and plans to build a CLIA-certified, CAP-accredited lab in the US later this year to support that product.
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.